Hansa Medical AB to Change Name to Hansa Biopharma AB

LUND, Sweden, Dec. 20, 2018 /PRNewswire/ --

Hansa Medical AB (publ) (Nasdaq Stockholm:HMED) ("Hansa Medical" or the "Company"), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the name change resolutions approved at an Extraordinary General Meeting ("EGM") held on December 4, 2018, have been approved by the 'Bolagsverket' in Sweden.

The name change will be implemented in the next days and weeks and the Company stock ticker symbol has changed from "HMED" to "HNSA". 

The information was submitted for publication, through the agency of the contact person set out below, at 2:15 pm CET on December 20, 2018. 

CONTACT:

For further information, please contact:

Company:

Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)

Mobile: +46-707-175477

E-mail:

Swedish Investor and Media Relations:

Cord Communications

Mikael Widell

+46-70-311-99-60

U.K. Investor and Media Relations

FTI Consulting

Simon Conway/ Stephanie Cuthbert 

+44 (0)20 3727 1000

U.S. Investor and Media Relations:

Argot Partners

Stephanie Marks/ David Rosen (media)

+1-212-600-1902

This information was brought to you by Cision

The following files are available for download:

View original content:

SOURCE Hansa Medical